HDAC9 and hematologic disorder: Currently, most HDAC inhibitors are pan-HDAC inhibitors, including Vorinostat (suberoylanilide hydroxamic acid, SAHA), Romidepsin, Belinostat, and Panobinostat, which have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hematological malignancies [17].